fda compounding glp-1 enforcement news today 2025 March 31, 2025: Senator asks how will be accountable for unregulated active pharmaceutical ingredient (API) imports – Partnership for Safe Medicines FDA Offers Clarification on Compounded

A 2022 meta-analysis published in JAMA Internal Medicine suggested a modest but statistically significant increase in cholelithiasis risk amongst GLP-1 agonist users, with higher risks observed at higher doses and with longer treatment duration

Effect of a polyherbal formulation on L-thyroxine induced hyperthyroidism in a rat model: In vitro and in vivo analysis and identification of bioactive phytochemicals

They also meet rising demand for clean label, functional products, particularly among those prioritizing digestive and metabolic health, she said

The mean final adult height and final adult height SDS among prepubertal naive-to-mecasermin patients were 158.6 cm (SD = 12.6) and 2.3 (SD = 1.2), respectively

Fewer months of living with obesity-related health risks